Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PAVmedFRA:1P5 -2.25%35 FCF Yield % is -15.98 as of Aug. 04, 2026. GuruFocus rates FRA:1P5 with a GF Score™ of 35/100 and a GF Value™ of €0.93 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 853 Medical Devices & Instruments companies, PAVmed ranks worse than 79.02% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, PAVmed's Trailing 12-Month Free Cash Flow is €-5.42 Mil, and Market Cap is €34.11 Mil. Therefore, PAVmed's FCF Yield % for today is -15.98%.
The historical rank and industry rank for PAVmed's FCF Yield % or its related term are showing as below:
FRA:1P5'
s FCF Yield % Range Over the Past 10 Years
Min: -772.17 Med: -106.57 Max: -5.24
Current: -15.98
During the past 12 years, the highest FCF Yield % of PAVmed was -5.24%. The lowest was -772.17%. And the median was -106.57%.
FRA:1P5's FCF Yield % is ranked worse than 79.02% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: -0.4
vs FRA:1P5: -15.98
PAVmed's FCF Margin % for the quarter that ended in Mar. 2026 was -12,026.32%.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
PAVmed FCF Yield % Related Terms
PAVmed FCF Yield % Historical Data
* Premium members only.
The historical data trend for PAVmed's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1P5 vs BDMD, NSPR, TELA: FCF Yield % Comparison
For the Medical Devices subindustry, PAVmed's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PAVmed FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's FCF Yield % distribution charts can be found below:
* The bar in red indicates where PAVmed's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PAVmed (FRA:1P5) has a FCF Yield % of -15.98 as of Aug. 04, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on PAVmed and its competitors. According to the industry distribution chart, PAVmed ranks #674 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 79%.
Is PAVmed's FCF Yield % too high?
PAVmed's current FCF Yield % is -15.98. Based on the distribution chart, PAVmed ranks #674 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PAVmed has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PAVmed's FCF Yield % compare to BDMD and NSPR?
According to the Medical Devices & Instruments industry distribution chart, PAVmed ranks #674 out of 853 companies for FCF Yield %. This places PAVmed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on PAVmed and its competitors. PAVmed's current FCF Yield % is -15.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PAVmed stock overvalued right now?
Based on GuruFocus' analysis, PAVmed (FRA:1P5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.93, compared to a current price of €4.13 — trading 343.5% above its estimated fair value. The current FCF Yield % is -15.98. PAVmed's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For PAVmed (FRA:1P5), the current FCF Yield % is -15.98 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PAVmed (FRA:1P5) Overvalued in 2026?
Based on GuruFocus' analysis, PAVmed stock appears to be overvalued.
The current stock price of €4.13 is trading 343.5% above its estimated GF Value™ of €0.93.
GuruFocus considers PAVmed to be Significantly Overvalued.
Key valuation signals for FRA:1P5:
FCF Yield %: -15.98
GF Value™: €0.93 vs. price of €4.13 (343.5% above fair value)
No single metric tells the full story. See the FRA:1P5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
35GF Score
Get the complete analysis for FRA:1P5
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1P5 has been successfully added to your 
